Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies,[2] is a publicly traded[3] clinical stage gene therapy company located in Redwood City, California.[4] The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).[5]
 | |
| Company type | Public |
|---|---|
| Nasdaq: ADVM Russell 2000 Component | |
| Industry |
|
| Founded | 2006 |
| Founders |
|
| Headquarters | Redwood City, California |
Key people | |
Number of employees | 100 |
| Website | adverum |
History edit
Avalanche Biotechnologies was founded in 2006 by Tom Chalberg, Mark Blumenkranz, Mitchell Finer, and Steven Schwartz.[citation needed] Avalanche went public through an IPO in 2014, raising $102 million.[6]
In 2015, co-founder Tom Chalberg stepped down as CEO following Phase IIa trial results that were labeled as "iffy".[7]
In May 2016, Avalanche acquired Annapurna Therapeutics and changed its name to Adverum Biotechnologies.[8] It also changed its ticker symbol on the Nasdaq exchange from AAVL to ADVM.[8] In October 2016, former Annapurna Therapeutics CEO Amber Salzman became CEO of Adverum.[9]
In May 2018, CEO Amber Salzman left Adverum, and Chief Medical Officer Athena Countouriotis resigned after less than one year in the job.[10] In October 2018, Leone Patterson was named the new CEO of Adverum.[11]
In September 2019, Adverum announced six-month data from the first cohort of its phase I trial.[12] The stock price dropped 50% due to investor concerns over deterioration of vision that these trial subjects suffered, as well as several reports of occular inflammation.[12]
In June 2020, Laurent Fischer replaced Patterson as CEO of Adverum.[13]
In January 2022, the FDA granted Orphan Drug Designation to Adverum's ADVM-062, developed as a single intravitreal administration for blue-cone monochromacy by delivering a functional copy of the OPN1LW gene.[14]
In September 2022, Adverum announced that its first patient was dosed in the LUNA phase 2 clinical trial; the trial evaluates development for the treatment of wet age-related macular degeneration.[15][16]
References edit
- ^ "Our Leadership Team". Adverum Biotechnologies. Retrieved 7 April 2021.
- ^ "Adverum delays start of gene therapy PhI/II by one year, blames manufacturing". FierceBiotech. 14 October 2016. Retrieved 2021-04-23.
- ^ "Adverum Biotechnologies, Inc (AAVL)". NASDAQ.com. Retrieved 4 January 2016.
- ^ "Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA". finance.yahoo.com. Retrieved 2020-02-25.
- ^ "ADVM-022 Intravitreal Gene Therapy for Wet AMD - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-02-25.
- ^ Garde, Damian (2014-07-31). "Gene therapy biotech Avalanche banks $102M in an up-sized IPO". FierceBiotech. Archived from the original on 2021-04-13. Retrieved 2021-04-26.
- ^ Leuty, Ron (2015-07-27). "As CEO exits, gene therapy company continues tumble". San Francisco Business Times. Retrieved 2021-04-23.
- ^ a b "Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies". GlobeNewswire News Room. 2016-05-12. Retrieved 2020-02-25.
- ^ "Post-merger, gene therapy player Adverum makes Amber Salzman CEO, delays a clinical trial start". Endpoints News. Retrieved 2021-04-23.
- ^ Taylor, Nick Paul (2018-05-04). "Adverum loses CEO, CMO in quick-fire departures". FierceBiotech. Archived from the original on 2018-05-04. Retrieved 2021-04-23.
- ^ "Adverum CEO Leone Patterson leaves her post | exechange". exechange.com. Retrieved 2021-04-23.
- ^ a b "Adverum cannot hide under an avalanche of concerns". Evaluate.com. 2019-09-12. Retrieved 2021-04-24.
- ^ "Adverum Biotechnologies Announces Leadership Transition". GlobeNewswire News Room. 2020-06-15. Retrieved 2021-04-23.
- ^ David Hutton (January 6, 2022). "Adverum Biotechnologies gets Orphan Drug Designation from FDA for gene therapy candidate". Ophthalmology Times.
- ^ David Hutton (September 16, 2022). "Adverum Biotechnologies announces first subject dosed with Ixo-vec in the Phase 2 LUNA trial for treatment of wet AMD". Ophthalmology Times.
- ^ Noah Stansfield (September 16, 2022). "First Patient Dosed in Wet AMD Gene Therapy LUNA Trial". CGTlive.